S. Triantos

发表

A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.

B. Monk, R. Coleman, T. Herzog, 2020, Gynecologic oncology.

Long-term alpha-tocopherol supplementation is associated with lower serum vascular endothelial growth factor levels.

D. Albanes, J. Virtamo, P. Taylor, 2002, Anticancer Research.

Apalutamide for patients with metastatic castration-sensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trial

Choung-Soo Kim, D. Ye, K. Chi, 2021, Asian journal of andrology.

Molecular determinants associated with long-term response to apalutamide (APA) in nonmetastatic castration-resistant prostate cancer (nmCRPC).

F. Feng, E. Small, Justin Lucas, 2021 .

Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).

K. Bevans, N. Agarwal, D. Ye, 2021 .

Management of Fibroblast Growth Factor Inhibitor Treatment-emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.

R. Huddart, B. Mellado, S. Park, 2023, European urology open science.

Outcomes of Patients with Advanced Urothelial Carcinoma after Anti–programmed Death-(ligand) 1 Therapy by Fibroblast Growth Factor Receptor Gene Alteration Status: An Observational Study

A. Santiago-Walker, D. Papantoniou, A. Necchi, 2022, European urology open science.

LBA27 Erdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE study

T. Powles, A. Santiago-Walker, T. Kang, 2021, Annals of Oncology.

Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial

G. Demetri, P. LoRusso, L. Dirix, 2018, Investigational New Drugs.

Efficacy and safety of erdafitinib in adults with cholangiocarcinoma (CCA) with prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase 2 open-label, single-arm RAGNAR trial: Expansion cohort results.

G. Iyer, J. Tabernero, G. Folprecht, 2023, Journal of Clinical Oncology.

Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt).

R. Huddart, S. Park, J. Ku, 2023, Journal of Clinical Oncology.

Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA+CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 Norse study.

T. Powles, T. Kang, A. Siefker-Radtke, 2023, Journal of Clinical Oncology.

Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer

Robin L. Jones, B. Monk, G. Demetri, 2021, Cancer medicine.

Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non–muscle-invasive bladder cancer (HR-NMIBC) with FGFR3/2 alterations (alt) in THOR-2: Cohort 2 interim analysis results.

H. Nishiyama, V. Master, N. Vasdev, 2023, Journal of Clinical Oncology.